Ariad Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Ariad Pharmaceuticals's estimated annual revenue is currently $300M per year.
- Ariad Pharmaceuticals's estimated revenue per employee is $2,112,676
- Ariad Pharmaceuticals's total funding is $88.5M.
Employee Data
- Ariad Pharmaceuticals has 142 Employees.
- Ariad Pharmaceuticals grew their employee count by 0% last year.
Ariad Pharmaceuticals's People
Name | Title | Email/Phone |
---|
Ariad Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Ariad Pharmaceuticals?
ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company's development pipeline includes: a drug candidate that controls cell proliferation and nutrient uptake by tumors to treat cancer; a bone-targeted drug candidate to treat the complications of cancer that has spread to bone; a regulated protein therapy product candidate to treat anemia in which the production of erythropoietin is controlled in vivo using an orally administered drug; a T cell immunotherapy product candidate in which a non-immunosuppressive drug may be used to treat graft-vs-host disease following donor bone marrow transplantation - a therapy for cancer and other immune and blood diseases; and dual-action drug candidates that block bone resorption and stimulate bone formation to treat osteoporosis. ARIAD also has an exclusive license to pioneering technology related to the discovery, development, and use of drugs that modulate the NF-(kappa)B pathway, which has been implicated in many major diseases
keywords:N/A$88.5M
Total Funding
142
Number of Employees
$300M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ariad Pharmaceuticals News
Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical adviser of ... He served as a senior patent counsel at ARIAD Pharmaceuticals...
... chairman of the board of directors and former Bayer Pharma CEO, ... at Sanofi-Genzyme, ARIAD Pharmaceuticals, and Bristol Myers Squibb.
ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $22.6M | 142 | N/A | N/A |
#2 | $28.1M | 142 | N/A | N/A |
#3 | $27.4M | 143 | 5% | N/A |
#4 | $27.7M | 143 | 12% | $94.8M |
#5 | $41.5M | 143 | 36% | N/A |